Open AccessEffects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study
Author(s) -
Ann V. Schwartz,
Haiying Chen,
Walter T. Ambrosius,
Anil K. Sood,
Robert G. Josse,
Denise E. Bonds,
Adrian M. Schnall,
Eric Vittinghoff,
Douglas C. Bauer,
Mary Ann Banerji,
Robert M. Cohen,
Bruce P. Hamilton,
Tamara Isakova,
Deborah E. Sellmeyer,
Debra L. Simmons,
Amal ShibliRahhal,
Jeff D. Williamson,
Karen L. Margolis
Publication year - 2015
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2015-1215
Subject(s) - discontinuation , medicine , hazard ratio , confidence interval , proportional hazards model , rosiglitazone , cohort study , pioglitazone , diabetes mellitus , type 2 diabetes , endocrinology , receptor
In trials, thiazolidinediones (TZDs) increase fracture risk in women, but the effects of discontinuation are unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom